CVS Health Co. (NYSE:CVS) Shares Sold by Stephens Consulting LLC

Stephens Consulting LLC reduced its position in CVS Health Co. (NYSE:CVS) by 18.8% during the 1st quarter, according to its most recent filing with the SEC. The firm owned 867 shares of the pharmacy operator’s stock after selling 201 shares during the quarter. Stephens Consulting LLC’s holdings in CVS Health were worth $69,000 as of its most recent filing with the SEC.

A number of other large investors also recently bought and sold shares of the company. Atticus Wealth Management LLC boosted its holdings in CVS Health by 149.0% in the 4th quarter. Atticus Wealth Management LLC now owns 366 shares of the pharmacy operator’s stock valued at $29,000 after purchasing an additional 219 shares in the last quarter. USA Financial Formulas boosted its stake in shares of CVS Health by 573.2% in the fourth quarter. USA Financial Formulas now owns 377 shares of the pharmacy operator’s stock valued at $30,000 after buying an additional 321 shares in the last quarter. Ables Iannone Moore & Associates Inc. acquired a new position in CVS Health during the fourth quarter worth $32,000. Creekmur Asset Management LLC acquired a new stake in CVS Health in the fourth quarter valued at $34,000. Finally, Steph & Co. boosted its position in shares of CVS Health by 192.0% during the 1st quarter. Steph & Co. now owns 438 shares of the pharmacy operator’s stock worth $35,000 after purchasing an additional 288 shares in the last quarter. Hedge funds and other institutional investors own 80.66% of the company’s stock.

CVS Health Trading Up 1.2 %

Shares of NYSE CVS traded up $0.70 during midday trading on Friday, hitting $59.06. The stock had a trading volume of 14,343,538 shares, compared to its average volume of 11,322,786. The company has a fifty day moving average price of $59.56 and a 200 day moving average price of $70.13. The company has a market capitalization of $74.14 billion, a price-to-earnings ratio of 10.38, a PEG ratio of 0.56 and a beta of 0.53. CVS Health Co. has a 1-year low of $52.77 and a 1-year high of $83.25. The company has a quick ratio of 0.61, a current ratio of 0.81 and a debt-to-equity ratio of 0.78.

CVS Health (NYSE:CVS) last released its quarterly earnings data on Wednesday, May 1st. The pharmacy operator reported $1.31 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.69 by ($0.38). The business had revenue of $88.44 billion during the quarter, compared to analyst estimates of $89.33 billion. CVS Health had a return on equity of 13.53% and a net margin of 2.03%. CVS Health’s revenue was up 3.7% on a year-over-year basis. During the same period in the previous year, the company earned $2.20 EPS. On average, analysts predict that CVS Health Co. will post 7.02 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Edward J. Ludwig acquired 1,000 shares of the stock in a transaction on Thursday, May 2nd. The stock was bought at an average price of $53.88 per share, with a total value of $53,880.00. Following the completion of the transaction, the director now directly owns 21,630 shares of the company’s stock, valued at $1,165,424.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.24% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several analysts recently commented on CVS shares. SVB Leerink reiterated a “market perform” rating and issued a $60.00 price objective (down previously from $87.00) on shares of CVS Health in a research note on Wednesday, May 1st. Wells Fargo & Company lowered their price target on CVS Health from $76.00 to $60.00 and set an “equal weight” rating on the stock in a report on Tuesday, May 7th. UBS Group cut CVS Health from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $85.00 to $60.00 in a report on Thursday, May 2nd. Barclays dropped their price target on CVS Health from $78.00 to $63.00 and set an “equal weight” rating for the company in a research report on Thursday, May 2nd. Finally, Cantor Fitzgerald reissued a “neutral” rating and issued a $58.00 price objective on shares of CVS Health in a research note on Wednesday, June 12th. Eleven analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to MarketBeat, CVS Health currently has an average rating of “Moderate Buy” and an average target price of $75.05.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.